# Zucara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zucara-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.zucara.ca
- Total disclosed funding: $46M
- Latest round: Series B (May 1, 2025)
- Investors on record: 3

## About

Zucara Therapeutics Inc., based in Canada, develops innovative treatments for diabetes, focusing on preventing hypoglycemia in patients with Type 1 diabetes through its proprietary therapeutic solution ZT-01. Founded in 2015 and headquartered in Vancouver, Canada, Zucara Therapeutics Inc. is dedicated to creating therapies that address unmet medical needs in diabetes management. Richard Liggins serves as the founder, and Michael Midmer is the CEO. Zucara has successfully completed a total of 9 deals, In May 2025, Zucara Therapeutics Inc. raised USD 5 million in series B funding from returning investor JDRF T1D Fund. Other unspecified investors also participated in the round. Zucara Therapeutics is focused on developing a groundbreaking therapeutic solution, ZT-01, aimed at preventing hypoglycemia in individuals with diabetes, particularly Type 1 diabetes. This once-daily treatment works by targeting and blocking somatostatin type 2 receptors in the pancreas, thereby restoring the body’s ability to produce glucagon and counteract low blood sugar levels. The end users of this product include insulin-treated patients, who often face the risks associated with hypoglycemia, impacting their health, quality of life, and diabetes management. The company’s innovation offers a preventative measure as opposed to existing therapies, which primarily provide rescue solutions during hypoglycemic episodes. Zucara Therapeutics aims to market its products in North America and select European countries, reaching a diverse client base of healthcare providers and patients.Zucara Therapeutics has successfully raised substantial funding to support its development activities, including a USD 21.00 mn Series A financing in 2020 and a USD 20.00 mn Series B financing in 2024, involving strategic investments from firms such as the Perceptive Xontogeny Venture Fund and Sanofi. While specific revenue figures are not disclosed, Zucara’s financial model will likely involve partnerships with healthcare providers and potential collaborations with pharmaceutical companies. The company’s revenue generation strategy will involve the sale of its flagship product, ZT-01, once it completes clinical trials and receives necessary regulatory approvals.In May 2025, Zucara Therapeutics Inc. raised USD 5 million in series B funding from returning investor JDRF T1D Fund. Other unspecified investors also participated in the round. The company will use the May 2025 funding to support the development and trial of its ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes.

## Funding rounds

- Series B, May 1, 2025, $5M — JDRF T1D Fund
- Series B, Nov 12, 2024, $20M — Sanofi, Perceptive Advisors
- Series A, Mar 31, 2020, $21M — Perceptive Advisors

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A, Series B
- Sanofi — Series B
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B